GlassScriptPhysician profile
Diane C Kraft
NPI 1255541983
$456.37
in general payments reported to CMS, 2019-2025
10 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $11.06 · 2022: $77.19 · 2023: $16.16 · 2024: $22.14 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $122.20 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $109.87 | 2022-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $70.25 | 2019-2025 | Cardiomems |
| Itamar Medical INC | $41.29 | 2022 | |
| Philips North America LLC | $32.91 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Pfizer INC. | $23.74 | 2019 | |
| United Therapeutics Corporation | $17.74 | 2025 | Tyvaso |
| Lexicon Pharmaceuticals, INC. | $16.16 | 2023 | Inpefa |
| Lilly USA, LLC | $11.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Kraft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.